FDA Issues Complete Response Letter to Tiva

Teva Pharmaceutical Industries Ltd. TEVA announced today that it has received a complete response letter from the U.S. Food and Drug Administration for its supplemental New Drug Application for a lower-volume injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis.